NASDAQ:HPTX (HPTX) (HPTX) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free HPTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume786,899 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (HPTX) alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About (HPTX) Stock (NASDAQ:HPTX)Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company's products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company's products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.Read More Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... HPTX Stock News HeadlinesApril 10, 2024 | bbc.co.ukNigel Clough: "The manner of the performance is what pleased us most"April 10, 2024 | bbc.co.ukNigel Clough: "The manner of the performance is what pleased us most"May 3, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.February 6, 2024 | msn.comProfessional Faqs: How I Reversed My Hashimoto's Disease Naturally?February 5, 2024 | msn.comBuc-ee's in Mebane: City leaders to discuss traffic impacts Monday nightJanuary 29, 2024 | msn.comPower cuts in Bengaluru till end of the month; Check areas list, timingsOctober 7, 2023 | msn.comTen Hag praises Mason Mount's contribution since returning from injurySeptember 30, 2023 | msn.comWilliam Blount’s 1797 impeachment trial set precedent for future casesMay 3, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.September 30, 2023 | msn.comThe laws about falsifying your address to get into a better school in your stateSeptember 28, 2023 | msn.comPackers injury update puts David Bakhtiari in doubt for longer than expectedSeptember 28, 2023 | msn.comHammer of Thor! Son Kicks to Death Elderly Dad, Tells Cops He Wanted to Reach ‘Valhalla’March 30, 2023 | msn.comESA confirms cancellation of E3 2023March 30, 2023 | msn.comPunjab cops using drone to hunt AmritpalMarch 30, 2023 | msn.comMississippi State baseball score vs. South Carolina: Live updates from Dudy Noble FieldFebruary 9, 2023 | msn.comA 21-year-old who says she never got 'bad' sunburn or used a tanning bed was diagnosed with the deadliest type of skin cancerJanuary 24, 2023 | msn.comBrawlhalla reveals Battle Pass 7 release date, new Mode and moreJanuary 12, 2023 | msn.comTeenager arrested over shooting death of another teen in Central Lubbock, LPD saidDecember 27, 2022 | msn.com'Lampard looked physically ill' - National media make same blunt Everton point after Wolves defeatAugust 30, 2022 | msn.comReport: Forest could end transfer window with a bang as Marinakis eyes blockbuster £43m playerNovember 27, 2021 | msn.comSave a huge 47% off on this top-ranked EVGA 500W PSU for your ATX PC buildNovember 2, 2021 | msn.comDallas Area Weekday Events: Check Out What's HappeningSeptember 25, 2021 | msn.comThese Are the 12 Best Picnic Spots in DallasSeptember 7, 2021 | msn.comThis Week's Dallas Area EventsSee More Headlines Receive HPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (HPTX) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2015Today5/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:HPTX CUSIP44915N10 CIK1386858 WebN/A Phone+1-650-7457802FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report HPTX Stock Analysis - Frequently Asked Questions How were (HPTX)'s earnings last quarter? (HPTX) (NASDAQ:HPTX) posted its earnings results on Thursday, February, 26th. The biopharmaceutical company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.67. The biopharmaceutical company had revenue of $30.80 million for the quarter, compared to analysts' expectations of $24.60 million. (HPTX)'s revenue was up 65.6% compared to the same quarter last year. What other stocks do shareholders of (HPTX) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (HPTX) investors own include Tivity Health (TVTY), Bausch Health Companies (BHC), Berkshire Hills Bancorp (BHLB), Cognex (CGNX), The Cigna Group (CI), Cynosure (CYNO), Depomed (DEPO), Health Net (HNT), Infinity Pharmaceuticals (INFI) and Keryx Biopharmaceuticals (KERX). This page (NASDAQ:HPTX) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryCould Your Accounts Be Frozen?Allegiance GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Gold Grab of the CenturyColonial MetalsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsREAD THIS – If You Missed Out On The AI BoomBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (HPTX) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
